BioLine Rx (BioLine Rx) Interest Expense : $-2.14 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioLine Rx's interest expense for the three months ended in Dec. 2023 was $ 0.96 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.14 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioLine Rx's Operating Income for the three months ended in Dec. 2023 was $ -11.86 Mil. BioLine Rx's Interest Expense for the three months ended in Dec. 2023 was $ 0.96 Mil. BioLine Rx did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioLine Rx Interest Expense Historical Data

The historical data trend for BioLine Rx's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Interest Expense Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.25

-1.47

-0.98

-1.79

-2.14

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.95	-0.93	-1.34	-0.84	0.96

BioLine Rx Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.14 Mil.

BioLine Rx (NAS:BLRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioLine Rx's Interest Expense for the three months ended in Dec. 2023 was $0.96 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-11.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $7.92 Mil.

BioLine Rx's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

The higher the ratio, the stronger the company's financial strength is.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.